Supporting Woment with Breast Cancer to Prepare for Treatment (The Prepare Study)
Aims: To measure the impact of a mindfulness intervention instituted prior to surgery on patient anxiety for newly diagnosed breast cancer patients.
Diagnosis: Breast Cancer- Participants must enroll prior to breast surgery
Principal Investigator: Katherine Yao, MD
IRB Approval Number: EH20-134
Sponsor: Myra Rubenstein Weis Foundation and John Wayne Cancer Foundation
Contact: Interested patients may contact Sandra Simovic at 847.570.4227, ssimovic@northshore.org
Open to Enrollment: Yes
PROMPT-BC Patient Reported Observations on Medical Procedure Timeliness – Breast Cancer
Aims: To understand patient’s perspectives on the timeliness of the breast cancer diagnostic process and time to first treatment thru qualitative interviews.
Diagnosis: Breast Cancer
Principal Investigator: Katherine Yao, MD
IRB Approval Number: EH21-349
Sponsor: NorthShore University Healthsystem
Contact: Interested patients may contact Sandra Simovic at 847.570.4227, ssimovic@northshore.org
Open to Enrollment: Yes – Spanish speaking patients only
A Prospective, Multicenter Investigation of the da Vinci® Xi™ Surgical System in Nipple Sparing Mastectomy (NSM) Procedures
Aims: To evaluate the safety and effectiveness of the Vinci® Xi™ Surgical System, instruments and accessories in NSM procedures performed for prophylaxis.
Diagnosis: High Risk for Breast Cancer
Principal Investigator: Katharine Kopkash, MD
IRB Approval Number: EH19-074
Sponsor: NorthShore University Healthsystem
Contact: Interested patients may contact Sarah Rabbitt, RN, CCRP at 847.570.1681 or srabbitt@northshore.org
Open to Enrollment: Yes
S2007: AS2007, “A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases
Aims: The purpose of this study is to see if the drug Sacituzumab govitecan will help women with breast cancer whose cancer has spread to their brain.
Diagnosis: Breast Cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH22-225
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
EA1181: The CompassHER2 Trials (COMprehensive us of Pathological Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 adn tucatinib
Aims: The purpose is to see if patients who have no cancer after intial therapy and surgery need additional chemotherapy or would targeted treatments be enough.
Diagnosis: Breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH21-154
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
A011801: (CompassHERCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.
Aims: The purpose is to see if adding tucabinib to the standard treatment of T-DM1 is better than T-DM1 alone in preventing your cancer from returning.
Diagnosis: Breast cancer
Principal Investigator: Poornima Saha, MD
IRB Approval Number: EH21-013
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes